thiophenes has been researched along with Arteriosclerosis, Coronary in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (17.98) | 29.6817 |
| 2010's | 73 (82.02) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexopoulos, D; Xanthopoulou, I | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A | 1 |
| Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K | 1 |
| Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cayla, G; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Quilici, J | 1 |
| Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Bonello, L; Frère, C; Laine, M; Paganelli, F | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE | 1 |
| Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ | 1 |
| Chua, D; Nishi, C | 1 |
| Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M | 1 |
| Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V | 1 |
| Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T | 1 |
| Angiolillo, DJ; Curzen, N; Effron, MB; Gurbel, P; Jakubowski, JA; Li, W; Lipkin, F; Trenk, D; Vaitkus, P; Zettler, M | 1 |
| Drummer, OH; Gerostamoulos, D; Pilgrim, JL | 1 |
| Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ | 1 |
| Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F | 1 |
| Böhm, M; Gensch, C; Laufs, U; Pavlickova, V; Pöss, J; Schirmer, SH; Werner, CM; Wright, MB | 1 |
| Jover, E; Tello-Montoliu, A; Valdés, M | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Angiolillo, DJ; Bass, TA; Cho, JR; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R | 1 |
| Jelliffe, R | 1 |
| Antoniucci, D; Migliorini, A; Valenti, R | 1 |
| Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ | 1 |
| Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ | 1 |
| Gogo, P; Keating, FK; Raza, SS; Schneider, DJ; Seecheran, N | 1 |
| Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Grohs, K; Gruber, C; Jilma, B; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D | 1 |
| Holper, EM; Luna, M | 1 |
| Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY | 1 |
| Angiolillo, DJ; Franchi, F | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE | 1 |
| Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Cairns, JA; Eikelboom, J | 1 |
| Stone, GW | 1 |
| Schaerlig, E | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Grove, EL; Kristensen, SD | 1 |
| Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS | 1 |
| Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ | 1 |
| Menon, V; Raymond, C | 1 |
| Lip, GY; Shantsila, E; Tapp, L | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Busse, B; Kaiser, A; Mügge, A; Neubauer, H | 1 |
| Gratsianskiĭ, NA | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM | 1 |
| Tagarakis, GI | 1 |
| Doggrell, SA | 1 |
| Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B | 1 |
| Baker, BA; Effron, MB; Jakubowski, JA; Kulkarni, MP; Li, YG; Luo, J; Miller, DL; Small, DS; Winters, KJ; Zhu, B | 1 |
| Flaherty, MP; Johnston, PV; Rade, JJ | 1 |
| Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G | 1 |
| Brott, BC; Dobbs, JC; Hillegass, WB; Misra, VK; Papapietro, SE; Zoghbi, GJ | 1 |
| Bernlochner, I; Contant, CF; Guo, J; Hochholzer, W; Kastrati, A; Mega, JL; Morath, T; Neumann, FJ; O'Donoghue, ML; Sabatine, MS; Schömig, A; Sibbing, D; Stratz, C; Trenk, D; Valina, CM; Wiviott, SD | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Mavronasiou, E; Panagiotou, A; Plakomyti, TE; Xanthopoulou, I | 1 |
| Antoniucci, D; Bellandi, B; Carrabba, N; Grassellini, S; Migliorini, A; Parodi, G; Ramazzotti, E; Valenti, R; Venditti, F | 1 |
| Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H | 1 |
| Baker, RA; Bennetts, JS; Cardinal, T; Tully, PJ | 1 |
| Mutnick, JL | 1 |
| Alber, H; Eberli, F; Galatius, S; Gilgen, N; Jeger, R; Jensen, JS; Kaiser, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickli, H; Vuilliomenet, A | 1 |
| Bowman, TS; Dawkins, KD; Garratt, KN; Lee, DP; Liao, H; Nwachuku, CE; Rose, EM; Windle, KJ; Winters, KJ | 1 |
| Baker, BA; Bernlochner, I; Brown, PB; Gupta, N; Jakubowski, JA; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Winters, KJ; Zhou, C | 1 |
| Carbonell-Porras, A; Fernández-Ruiz, M; García-Reyne, A; López-Medrano, F | 1 |
| Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA | 1 |
| Steinhubl, SR | 1 |
| Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D | 1 |
| Dibattiste, PM; Ringwala, SM; Schneider, DJ | 1 |
| Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Huber, K | 1 |
| Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C | 1 |
| Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S | 1 |
| Mancini, GB | 1 |
| Araujo, CM; Cristóvão, SA; Mangione, JA; Mauro, MF; Oliveira Neto, JB; Rando, GA; Salman, AA; Sanchez, IS | 1 |
| Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ | 1 |
| Serebruany, VL | 1 |
| Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
| Das, MK; Iwai, S; Lerman, BB; Lomnitz, DJ; Markowitz, SM; Mirchandani, S; Mittal, S; Slotwiner, DJ; Stein, KM | 1 |
26 review(s) available for thiophenes and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[New antiplatelet drugs in coronary artery disease].
Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Use of novel antiplatelet agents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes | 2015 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2015 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on oral antiplatelet therapy: principles, problems and promises.
Topics: Adenosine; Administration, Oral; Cardiovascular Diseases; Cilostazol; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Tetrazoles; Thiophenes; Thromboxane A2; Ticagrelor | 2009 |
Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2010 |
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Young Adult | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2010 |
Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents.
Topics: Adenosine; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor | 2010 |
Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Topics: Amidines; Coronary Artery Disease; Cyclic N-Oxides; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Naphthalenes; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2011 |
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombosis; Time Factors; Treatment Outcome | 2011 |
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary Artery Disease; Data Interpretation, Statistical; Diabetes Mellitus; E-Selectin; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Thiophenes; Vasculitis | 2002 |
31 trial(s) available for thiophenes and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Topics: Adenosine; Adolescent; Adult; Aged; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Topics: Adenosine Monophosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Time Factors | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2014 |
Pharmacodynamic effects during the transition between cangrelor and prasugrel.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome | 2015 |
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Regression Analysis; Thiophenes; Ticlopidine | 2015 |
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria
Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome | 2015 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome | 2008 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2011 |
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.
Topics: Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Patient Compliance; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Treatment Outcome | 2012 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult | 2012 |
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Denmark; Drug-Eluting Stents; Female; Follow-Up Studies; Germany; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Purinergic P2Y Receptor Antagonists; Survival Rate; Switzerland; Thiophenes; Treatment Outcome | 2012 |
Rationale and design of the TAXUS Libertē Post-Approval Study: examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice.
Topics: Aged; Cardiology; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Device Approval; Drug-Eluting Stents; Equipment Design; Female; Follow-Up Studies; Humans; Male; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome | 2012 |
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes | 2012 |
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
32 other study(ies) available for thiophenes and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Coronary Artery Disease; Drug Substitution; Female; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Blood Platelets; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Off-Label Use; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
The impact of the environment on diseases and drugs.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Pilot Projects; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States | 2014 |
The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009-2012).
Topics: Adult; Aged; Antidepressive Agents; Australia; Cardiomegaly; Cause of Death; Chromatography, Liquid; Cohort Studies; Coronary Artery Disease; Coroners and Medical Examiners; Drug Interactions; Duloxetine Hydrochloride; Female; Forensic Toxicology; Humans; Male; Middle Aged; Pharmaceutical Preparations; Prevalence; Pulmonary Edema; Tandem Mass Spectrometry; Thiophenes | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine | 2014 |
The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Case-Control Studies; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Artery Disease; Disease Models, Animal; Endothelial Cells; Hindlimb; Humans; Ischemia; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; PPAR gamma; Signal Transduction; Stem Cells; Thiophenes | 2014 |
Concerning antiplatelet therapy.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Concerning antiplatelet therapy. Reply.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2016 |
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure | 2008 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
[American Heart Association conference 2008. The JUPITER trial, the approval of prasugrel, the (aging) heart of obese adolescents].
Topics: Adolescent; Adolescent Nutritional Physiological Phenomena; American Heart Association; Cardiovascular Diseases; Cholesterol; Congresses as Topic; Coronary Artery Disease; Drug Approval; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Obesity; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; United States | 2009 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation--a preliminary study.
Topics: Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Stents; Thiophenes | 2010 |
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome | 2011 |
Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft surgery.
Topics: Aged; Aged, 80 and over; Australia; Coronary Artery Bypass; Coronary Artery Disease; Cyclohexanols; Depression; Duloxetine Hydrochloride; Female; Follow-Up Studies; Hospital Mortality; Humans; Kidney Diseases; Male; Middle Aged; Postoperative Hemorrhage; Proportional Hazards Models; Renal Dialysis; Respiration, Artificial; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2012 |
Desensitization to prasugrel: cardiology's increased need for allergy consultation.
Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Dosage Calculations; Drug Hypersensitivity; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Stents; Thiophenes; Ticlopidine | 2012 |
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
The illusion of "optimal" platelet inhibition.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Blood Platelets; Cardiovascular Diseases; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Tirofiban; Tyrosine | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult | 2012 |
[Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study].
Topics: Adult; Brazil; Catheterization; Coronary Artery Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Phenylalanine; Pilot Projects; Prospective Studies; Protease Inhibitors; Stents; Thiophenes | 2005 |
Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Prognostic significance of nonsustained ventricular tachycardia after revascularization.
Topics: Academic Medical Centers; Aged; Arrhythmias, Cardiac; Cause of Death; Coronary Artery Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Follow-Up Studies; Humans; Male; Myocardial Revascularization; New York City; Prognosis; Retrospective Studies; Survival Rate; Tachycardia, Ventricular; Thiophenes; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |